Does BORTEZOMIB Cause Second primary malignancy? 87 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 87 reports of Second primary malignancy have been filed in association with BORTEZOMIB (bortezomib). This represents 0.2% of all adverse event reports for BORTEZOMIB.
87
Reports of Second primary malignancy with BORTEZOMIB
0.2%
of all BORTEZOMIB reports
24
Deaths
21
Hospitalizations
How Dangerous Is Second primary malignancy From BORTEZOMIB?
Of the 87 reports, 24 (27.6%) resulted in death, 21 (24.1%) required hospitalization, and 10 (11.5%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BORTEZOMIB. However, 87 reports have been filed with the FAERS database.
What Other Side Effects Does BORTEZOMIB Cause?
Plasma cell myeloma (6,683)
Off label use (4,754)
Neuropathy peripheral (4,067)
Drug ineffective (2,730)
Diarrhoea (2,244)
Thrombocytopenia (2,082)
Death (2,025)
Pneumonia (2,020)
Fatigue (1,757)
Neutropenia (1,530)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BORTEZOMIB Alternatives Have Lower Second primary malignancy Risk?
BORTEZOMIB vs BOSENTAN
BORTEZOMIB vs BOSENTAN\BOSENTAN
BORTEZOMIB vs BOSULIF
BORTEZOMIB vs BOSUTINIB
BORTEZOMIB vs BOTOX